Abivax is a Paris-based biotech firm founded in 2013, dedicated to creating treatments that leverage the body's immune system to fight chronic inflammatory diseases. Its flagship product, obefazimod, is currently in Phase 3 trials, targeting the treatment of ulcerative colitis. By focusing on the body's natural regulatory mechanisms, Abivax aims to offer innovative solutions for patients with severe health conditions.
Pre-Market Stock Futures: Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up…
Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the…
